Thermo Fisher Executive Outlines AI Driven Quality Framework to Accelerate Pharmaceutical Development Timelines

Thermo Fisher Scientific’s Anil Kane explains how AI and Quality by Design (QbD) are streamlining drug development for safer, faster patient access.

By: AXL Media

Published: Apr 29, 2026, 8:20 AM EDT

Source: Information for this report was sourced from Thermo Fisher Scientific

Integrating Quality Systems into the Pharmaceutical Lifecycle

At the core of modern pharmaceutical advancement is the transition from reactive testing to a proactive framework where quality is a fundamental design element rather than an afterthought. According to Anil Kane, Executive Director at Thermo Fisher Scientific, the development journey, which spans five to twelve years, relies entirely on the integrity of input data to guide critical go, no-go decisions. By embedding quality at the conceptual stage, developers can ensure that the scientific strategy remains robust as a molecule moves from initial discovery through clinical trials and eventual commercialization.

Phase Appropriate Analytical Strategies in Early Research

The rigor of quality control must evolve in tandem with the drug’s development phase, balancing regulatory flexibility with scientific reliability. In the early stages of a program, analytical methods do not require the full validation essential for commercial release, yet they must be sufficiently robust to support toxicological and first-in-human trials. According to Kane, early molecular characterization is non-negotiable, requiring precise assessments of salt forms, stability, and bioavailability. This foundational data prevents the accumulation of technical debt, where unaddressed issues in early research manifest as insurmountable hurdles during late-stage manufacturing.

The Role of Artificial Intelligence in Predictive Modeling

The pharmaceutical industry is currently undergoing a digital transformation as traditional neural networks evolve into sophisticated artificial intelligence and machine learning systems. These tools are now capable of analyzing massive datasets to predict a molecule’s solubility, absorption, and excipient compatibility before physical testing even begins. By utilizing AI to narrow down candidate pools to only the most promising leads, researchers can significantly reduce the trial and error cycles that historically extended development timelines and inflated costs.